Rezatapopt NDA Clock Starts With Phase 1 Evidence, Three Withdrawal Shadows, and a Q2 2027 Cash Cliff

PMV Pharma Completes PYNNACLE Phase 2 Enrollment, Plans Q1 2027 NDA

PMV Pharmaceuticals announced the completion of enrollment for the primary analysis in the Phase 2 monotherapy portion of its PYNNACLE clinical trial for rezatapopt. The company anticipates submitting a New Drug Application (NDA) for accelerated approval of rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027. Financially, PMV Pharma reported $79.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing an expected cash runway through the second quarter of 2027. The net loss for the second quarter of 2026 was $18.1 million, an improvement from $21.2 million in the prior year.

• PMV Pharmaceuticals has successfully completed enrollment for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial. This registrational, single-arm study is evaluating rezatapopt as a monotherapy in patients with TP53 Y220C advanced solid tumors, specifically focusing on platinum-resistant/refractory ovarian cancer for the primary analysis.
• The company is on track to submit a New Drug Application (NDA) for accelerated approval of rezatapopt for platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027. This regulatory pathway is supported by the U.S. FDA's prior grants of Fast Track designation for advanced solid tumors and Orphan Drug Designation for TP53 Y220C positive ovarian cancer.
• PMV Pharma maintains a solid financial position, reporting $79.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026. This capital is projected to fund the company's operations and ongoing development activities, including the rezatapopt program, through the second quarter of 2027, demonstrating financial stability for its clinical pipeline.
• Rezatapopt (PC14586) is highlighted as a first-in-class, small molecule, p53 reactivator. It is specifically designed to selectively bind to a pocket in the p53 Y220C mutant protein, thereby restoring its wild-type tumor-suppressor function, addressing a critical oncogenic pathway in approximately half of all cancers.

Addressing Key Challenges in Platinum-Resistant Ovarian Cancer

Platinum-resistant ovarian cancer (PROC) remains one of the most therapeutically intractable malignancies, defined by disease recurrence within six months of completing platinum-based chemotherapy. Despite active investigation across multiple treatment modalities, outcomes remain poor and no combination regimen has consistently outperformed standard chemotherapy in this setting.

• Poor clinical outcomes with current standard-of-care: PROC is associated with persistently low response rates and limited survival benefit. In the NRG-GY023 trial, median progression-free survival across all treatment arms ranged from only 2.5 to 3.4 months, median overall survival from 5.7 to 10.2 months, and objective response rates from 4.3% to 15.9% — underscoring the inadequacy of existing approaches.

• Failure of novel combination strategies to improve upon chemotherapy: Promising mechanistically-driven combinations have not translated into clinical benefit. The NRG-GY023 trial, evaluating durvalumab plus olaparib and cediranib (DOC), durvalumab plus cediranib (DC), and olaparib plus cediranib (OC) versus standard-of-care chemotherapy, was closed early due to futility, with hazard ratios of 1.003, 1.108, and 1.021 for DOC, DC, and OC respectively — none demonstrating progression-free survival improvement.

• Significant treatment-related toxicity burden: Both investigational and standard agents carry clinically meaningful toxicity profiles. Etirinotecan pegol was associated with grade 3/4 rates of diarrhea (20%), abdominal pain (17%), vomiting (14%), dehydration (13%), and nausea (13%). Peripheral neuropathy remains a persistent concern, occurring in 28% of paclitaxel-treated patients versus 14% with nab-paclitaxel.

• Complex and heterogeneous resistance mechanisms: Platinum resistance arises through multiple convergent pathways, including altered cellular pharmacology limiting platinum-DNA adduct formation and disrupted DNA repair and cell cycle regulation. High-grade serous ovarian carcinoma is further characterized by universal TP53 mutations, widespread genomic instability with copy number variations, and homologous recombination deficiency in over 50% of cases — with restoration of homologous recombination representing a key acquired resistance mechanism driving patient mortality.

• Absence of validated predictive biomarkers: The clinical definition of platinum resistance based on a six-month recurrence interval is increasingly complicated by advances in imaging and serum marker sensitivity. The molecular heterogeneity of PROC, combined with a lack of validated predictive biomarkers, significantly impedes the development of effective biomarker-driven treatment selection strategies.

Rezatapopt's Precision Approach: Targeting TP53 Y220C

Rezatapopt's patient selection strategy is anchored in a single, precisely defined genetic criterion: the presence of the TP53 Y220C somatic mutation in tumor tissue. This missense mutation destabilizes the p53 protein by creating a surface cavity that accelerates thermal unfolding, and rezatapopt is designed to selectively bind and stabilize this conformational variant without engaging wild-type or alternative mutant p53 isoforms. As a result, confirmed TP53 Y220C status served as the fundamental enrollment criterion across trials, including the Phase 1 PYNNACLE study, which enrolled heavily pretreated patients with locally advanced or metastatic solid tumors harboring this specific alteration.

Beyond TP53 Y220C, the PYNNACLE trial identified KRAS mutation status as a clinically meaningful stratification biomarker. The overall confirmed response rate across the enrolled population was 20%; however, this rose to 30% among patients with KRAS wild-type tumors receiving a dose of at least 1,150 mg once daily. Notably, all patients who achieved a confirmed response harbored both TP53 Y220C and wild-type KRAS, positioning co-mutation status as a potentially important determinant of benefit. Responses were observed across multiple solid tumor histologies, with ovarian and breast cancers among the represented types.

Resistance profiling was also integrated into the trial framework as a translational biomarker strategy. Serial analysis of circulating tumor DNA, on-treatment tumor biopsies, and rapid autopsy specimens obtained at disease progression were used to characterize acquired resistance mechanisms. This approach revealed secondary TP53 alterations occurring in cis with the Y220C mutation, providing molecular insight into treatment escape and informing future combination or sequencing strategies.

PYNNACLE Trial Design: Defining the Patient Population

Pivotal trials in platinum-resistant/refractory ovarian cancer employ carefully defined eligibility criteria to ensure a homogeneous, evaluable patient population while mitigating safety risks inherent to this heavily pre-treated cohort. Criteria span disease characterization, biomarker status, and prior treatment history, and have evolved meaningfully in response to emerging toxicity and efficacy data.

• Disease status and measurability: Eligible patients must have confirmed platinum-resistant or platinum-refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer, with documented disease progression following the last prior line of therapy. Measurable disease is required per RECIST 1.1 criteria or, alternatively, meeting GCIG CA125 criteria.

• Biomarker-driven inclusion: For trials evaluating folate receptor alpha (FRα)-targeted agents such as mirvetuximab soravtansine, a minimum threshold of FRα positivity by immunohistochemistry — defined as ≥25% of tumor cells demonstrating at least 2+ staining intensity — is mandated as an enrollment prerequisite, reflecting the mechanistic dependency of antibody-drug conjugate activity on target expression.

• Prior treatment requirements: Trial designs specify prior chemotherapy exposure in the recurrent setting as an inclusion condition. Conversely, certain combination trials — such as those evaluating cediranib/olaparib — explicitly excluded patients who had received prior PARP inhibitors or anti-angiogenic agents in the recurrent setting, preserving the mechanistic rationale of the investigational regimen.

• Bevacizumab-specific gastrointestinal exclusions: Anti-angiogenic trials, particularly those incorporating bevacizumab, implemented dedicated exclusion criteria to mitigate bowel perforation risk — specifically, clinical symptoms of bowel obstruction, rectosigmoid involvement on pelvic examination, or bowel involvement identified on CT imaging. These criteria were introduced following an initial phase II experience reporting an 11% bowel perforation incidence, and their application successfully reduced this complication to zero in screened cohorts.

The Evolving Treatment Landscape for Ovarian Cancer

The treatment landscape for platinum-resistant/refractory ovarian cancer (PROC) has undergone a meaningful shift over the past five years, moving away from reliance on single-agent cytotoxic chemotherapy toward biomarker-selected, targeted approaches. PARP inhibitors have demonstrated clinically relevant activity in BRCA-mutated PROC, with pamiparib achieving an objective response rate (ORR) of 31.6% (95% CI, 12.6–56.6) in germline BRCA-mutated patients following at least two prior lines of therapy. Olaparib monotherapy, evaluated in the CLIO/BGOG-ov10 trial, showed an overall ORR of 17.9% in PROC, with substantially higher activity in BRCA-mutated cases (35.7%) versus BRCA-wildtype cases (13.2%). Notably, in heavily pretreated patients with more than four prior lines, olaparib achieved an ORR of 22.9% compared to 0% for chemotherapy, underscoring the relevance of molecular selection in this setting.

Antibody-drug conjugates have emerged as a particularly compelling advance, most notably mirvetuximab soravtansine for folate receptor alpha (FRα)-positive PROC. In the SORAYA study, mirvetuximab demonstrated an ORR of 32.4% (95% CI, 23.6–42.2) with a median duration of response of 6.9 months in FRα-high patients who had received one to three prior therapies including bevacizumab. Meta-analytic data further corroborated these findings, with a pooled ORR of 29% (95% CI, 25–32%) and a median progression-free survival (PFS) of 6.26 months in platinum-resistant disease. The tolerability profile — predominantly grade 1–2 blurred vision (43%), nausea (41%), diarrhea (39%), and fatigue (35%) — compared favorably with conventional chemotherapy. The combination of mirvetuximab with pembrolizumab in heavily pretreated PROC patients yielded an ORR of 31% (95% CI, 19–45), a median duration of response of 8.0 months, and a median PFS of 4.2 months, with activity maintained across multiple prior lines of treatment.

Rational combinations incorporating immunotherapy and anti-angiogenic agents have also been investigated, with mixed but informative results. The NRG-GY005 trial evaluating cediranib plus olaparib versus standard-of-care chemotherapy demonstrated a median PFS of 5.2 versus 3.4 months and an ORR of 24.7% versus 8.6%, though statistical superiority was not achieved. The EORTC 1508-GCG study of bevacizumab plus atezolizumab showed a median PFS of 4.1 versus 2.3 months for bevacizumab monotherapy, with exploratory analyses suggesting potential benefit in patients with high tumor-infiltrating lymphocytes and baseline PD-L1-positive tumors. Ongoing efforts, including the AGO-OVAR 2.29/ENGOT-ov34 trial testing atezolizumab added to non-platinum chemotherapy and bevacizumab, reflect the continued drive to improve overall survival in this population — an endpoint that remains a significant unmet need despite the incremental advances achieved across these modalities.

Targeting p53 Y220C: A New Frontier in Ovarian Cancer

The completion of primary analysis enrollment for rezatapopt's Phase 2 monotherapy in platinum-resistant/refractory ovarian cancer marks a pivotal moment for PMV Pharmaceuticals and the broader oncology landscape. Rezatapopt is a first-in-class small molecule designed to reactivate the p53 Y220C mutant protein, a specific genetic alteration found in a subset of human cancers. This targeted approach aims to restore the crucial tumor suppressor functions of p53, offering a novel therapeutic strategy for patients with limited treatment options.

The company's intent to pursue accelerated approval in the first quarter of 2027 highlights the significant unmet need in platinum-resistant/refractory ovarian cancer. If successful, this could establish rezatapopt as a foundational therapy in a niche but critical patient population. Beyond ovarian cancer, the validation of this p53 reactivation mechanism could pave the way for broader development across other solid tumors harboring the TP53 Y220C mutation, where early studies have shown promising antitumor activity. However, the success of this strategy hinges on robust patient identification through companion diagnostics, which will be crucial for market penetration.

Several considerations warrant attention as rezatapopt progresses. While Phase 1 data demonstrated proof of concept with an overall response rate of 20% (30% in KRAS wild-type tumors), the bar for accelerated approval in this challenging indication remains high. The safety profile, including a 16% incidence of Grade 3 or higher anemia and common gastrointestinal adverse events, will be closely scrutinized for its impact on patient tolerability and long-term adherence. Furthermore, the company's financial runway, projected through Q2 2027, is tightly coupled with the anticipated NDA submission timeline, leaving little room for unexpected regulatory delays. The coming quarters will be critical in determining whether this innovative approach can translate into a meaningful new option for patients.